Guillaume Bouguen's research while affiliated with Université de Rennes 2 and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (284)
Background
Switches to biosimilars (BioS) are not always well-accepted by patients. Patients’ beliefs, concerns, and knowledge about health could impact their satisfaction towards switching.
Objectives
To analyse patient beliefs about medicine and health knowledge that may impact patients’ satisfaction after a switch to a BioS of adalimumab.
Meth...
Background
Switching from a reference product (RP) to a biosimilar (BS) aims to generate savings. Patient adherence after a switch is linked to overall experience that can be impacted by patient or treatment characteristics.
Objectives
This study aimed to analyse patient-experience and satisfaction after the switch from an adalimumab (ADA) RP or B...
Background
Both vedolizumab and ustekinumab can be considered for the treatment of ulcerative colitis [UC], but head-to-head trials are lacking.
Aim
We aimed to compare the effectiveness of vedolizumab and ustekinumab after anti-tumour necrosis factor [anti-TNF] failure in UC patients.
Patients and Methods
In this multicentre study, we included c...
Aims
In patients with ulcerative colitis (UC), no biomarker is available to help the physician to choose the most suitable biotherapy. The primary objective of this pilot study was to assess the feasibility of identification of α4β7- and TNF-expressing cells, to predict the response to vedolizumab using confocal laser endoscopy (CLE).
Methods
Pati...
Background
Achieving deep and continuous remission with tight control could allow de-escalation in patients with UC. The in-TARGET study was a prospective two-phase trial in UC patients initiating golimumab (GLM), that aimed to determine the proportion of patients with continuous clinical response (CCR) and endoscopic remission (ER) after one year...
Background
Switching from a reference product (RP) to a biosimilar (BS) aims at generating cost savings. Patient adherence after a switch is linked to overall experience that can be impacted by patient or treatment characteristics. This study aimed to analyse patient-experience after a switch from an adalimumab (ADA) to CT-P171 (ADA BS high concent...
Background
Vedolizumab is often used as the first-line advanced therapy for patients with moderate to severe ulcerative colitis (UC). There is currently no data reporting the efficacy and safety of second-line treatments after initial vedolizumab failure. The objective of our study was to compare the efficacy of anti-TNF, ustekinumab, and tofacitin...
Background
In patients admitted for acute severe ulcerative colitis (ASUC) responding to intravenous (IV) steroids, the most effective treatment is unknown. In thiopurine-naive patients, thiopurines are appropriate to maintain remission according to current guidelines while the benefit of early infliximab (IFX) therapy remains to be established.
M...
Background
Prospective data after switch from intravenous infliximab (IV-IFX) to subcutaneous (SC-IFX) in Inflammatory Bowel Disease (IBD) is needed. The aim of this prospective multicenter cohort was to describe SC-IFX persistence, efficacy and tolerance after switch from IV-IFX.
Methods
IBD patients in steroid-free clinical remission (defined by...
Background
STRIDE 2 recommendations define clinical remission as no rectal bleeding and normalization of stool frequency in patients with ulcerative colitis (UC), without including bowel urgency (BU) despite its negative impact on quality of life.
In this large multicenter cohort, we aimed to assess whether the persistence of BU after induction the...
Aim:
The aim of this study was to evaluate the real-life clinical and radiological efficacy of darvadstrocel injection into complex perianal fistulas in Crohn's disease. Secondary endpoints were to assess symptomatic efficacy, adverse effects and factors associated with complete combined clinical-radiological response (deep remission).
Methods:...
Background
Although ulcerative proctitis [UP] can dramatically impair quality of life, treatment efficacy has been poorly investigated in UP as it was historically excluded from phase 2/3 randomised controlled trials in ulcerative colitis. Our aim was to assess the effectiveness and safety of tofacitinib for the treatment of UP.
Methods
We conduct...
Background
Patients with inflammatory bowel disease (IBD) may have a modified immune response to SARS-CoV-2. The objectives were to evaluate the prevalence of COVID-19 in patients treated with infliximab or vedolizumab, to analyze the factors associated with the infection, the impact of treatments and trough levels.
Methods
Patients with IBD treat...
Background and aims:
Extraintestinal manifestations (EIM) of inflammatory bowel disease (IBD) are challenging clinical situation. No prospective study assessed remission risk factors for EIMs. Study aimed to prospectively investigate the epidemiology, risk factors for EIM occurrence and EIM remission in a large IBD cohort.
Methods:
We conducted...
Background:
The risk of relapse after anti-tumour necrosis factor [TNF] therapy discontinuation in Crohn's disease patients with perianal fistulas [pCD] is unclear. We aimed to assess this risk.
Methods:
A systematic literature search was conducted to identify cohort studies on the incidence of relapse following anti-TNF discontinuation in pCD p...
Mucosal healing has emerged as a therapeutic goal to achieve lasting clinical remission in ulcerative colitis. Intestinal repair in response to inflammation presumably requires higher energy supplies for the restoration of intestinal barrier and physiological functions. However, epithelial energy metabolism during intestinal mucosal healing has bee...
Background
Patients experience may be negatively impacted when starting biosimilar due to a poorly executed switch which could result in poor adherence and nocebo effect.
Objectives
This study aims to identify suitable patient satisfaction dimensions to design an observational study on real-life switches.
Methods
A qualitative exploratory study w...
Background:
In recent years, an increasing prevalence of obesity in inflammatory bowel disease (IBD) has been observed. However, only a few studies have focused on the impact of overweight and obesity on IBD-related disability.
Aims:
To identify the factors associated with obese and overweight patients with IBD, including IBD-related disability....
Background:
Fatigue is commonly reported by patients with inflammatory bowel disease (IBD), but the determinants of IBD-related fatigue have yet to be determined.
Aims:
To identify the factors associated with fatigue in a large population of patients with IBD.
Patients and methods:
Fatigue and nine other IBD-related disability dimensions were...
Simple Summary
Crohn’s disease (CD) is associated with an increased risk of small bowel neoplasia (SBN). We aimed to assess preoperative predictors of SBN in CD patients. We conducted a retrospective case-control study including CD patients who underwent surgery: cases were diagnosed with SBN on histopathological analysis in 12 tertiary centres and...
Purpose:
The aim of this study was to evaluate the real-life clinical and radiological efficacy of darvadstrocel injection into complex perianal fistulas in Crohn’s disease. Secondary endpoints were to assess symptomatic efficacy, outcomes and factors associated with complete combined clinical-radiological response (deep response).
Methods:
After m...
Background
There is no biomarker to guide first-line of biotherapy in ulcerative colitis (UC). The main objective of this multicenter pilot study was to demonstrate the feasibility of identifying a4b7 and/or TNF-a expressing cells by dual-band confocal endomicroscopy (CLE) into the mucosa to predict the response to vedolizumab as first-line biother...
Background
While the effect of anti-TNFs on postoperative outcomes in patients with Crohn's disease (CD) has been widely studied, the impact of vedolizumab and ustekinumab on the risk of postoperative complications remains poorly known.
Methods
All consecutive patients who underwent intestinal resection for CD between July 2014 and April 2022 with...
Background
Endoscopy remains the gold standard in Crohn’s disease (CD) to assess mucosal healing but remains invasive and costly. Mucosal healing is the target to reach in current therapeutic strategies because of its association with improve CD outcomes. Fecal calprotectin is still only a surrogate marker due to the lack of data on its ability to...
Background
We aimed to compare the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis (UC) previously exposed to at least one anti-TNF agent.
Methods
In this multicenter study, we retrospectively included consecutive UC adult patients previously exposed to at least one anti-TNF agent, with partial Mayo score (pMS) > 2...
Background
Transmural healing (TH) is associated with better outcomes that endoscopic remission in Crohn’s disease (CD) but is not yet considered as therapeutic target owing to the lack of validated and consensual definition.
In the DEVISE-CD project, we aimed to 1) build and validate a dedicated score to assess transmural response (TR) and TH in C...
Background
Subcutaneous infliximab (IFX-SC) was launched in France for the treatment of patients with inflammatory bowel disease (IBD) in 2021. Real-life and pharmacokinetic (PK) data after switching from intravenous infliximab (IFX-IV) to IFX-SC are needed. The PEREM study is a French multicenter prospective cohort aiming to describe the persisten...
Background
The combination of infliximab and immunosuppressant therapy is a standard management strategy for patients with Crohn's disease. Concerns regarding the implications of long-term combination therapy provided the rationale for a formal clinical trial of treatment de-escalation. Our aim was to compare the relapse rate and the time spent in...
Background
Whether healthcare workers with inflammatory bowel disease (IBD) are at increased risk of Novel coronavirus disease (COVID-19) due to occupational exposure is unknown.
Aim
To assess the risk of COVID-19 in healthcare workers with IBD.
Methods
A case control study enrolled 326 healthcare workers with IBD from 17 GETAID centres and match...
Background
No study has performed a face-to-face comparison of biologics after the failure of the first anti-TNF agent in patients with Crohn’s disease (CD). The aim of the study was to compare the efficacy of biologics in this setting.
Methods
Patients with CD who were refractory to a first anti-TNF agent, and treated with ustekinumab (UST), vedo...
Background:
The outcomes of bariatric surgery (BS) in patients with chronic inflammatory bowel disease (IBD) remain rarely described. We aimed to evaluate the 90-day morbidity and mortality rates, and the risk of IBD complications 2 years after BS.
Method:
Patients from the French Programme de Médicalisation des Systèmes d'Information (PMSI) dat...
Background
Data comparing tofacitinib and vedolizumab in ulcerative colitis (UC) are lacking.
Aims
To compare the effectiveness of tofacitinib and vedolizumab in patients with UC who had prior exposure to anti‐TNF therapy
Methods
In this multicentre study, we included consecutive patients with UC ≥18 years old with partial Mayo score >2 and prior...
Abstract The role of intestinal bacterial microbiota has been described as key in the pathophysiology of Crohn’s disease (CD). CD is characterized by frequent relapses after periods of remission which are not entirely understood. In this paper, we investigate whether the heterogeneity in microbiota profiles in CD patients could be a suitable predic...
Aims:
The aims of our study were to assess the best medical and surgical approaches for Perianal Crohn's Disease (PCD) in order to identify an optimal combined medical and surgical treatment.
Methods:
Medical records of all patients with PCD treated with TNFα antagonists in two referral centers between 1998 and 2018 were reviewed. Predictors of...
Background
Since our last publication of algorithms for the management of perianal fistulas in patients with Crohn’s disease, researchers have proposed a treat to target strategy systematic combotherapy for anal lesions, and indications for stem cell injection. In the absence robust publications, the Société Nationale Française de Coloproctologie (...
Background
Use of a combination of targeted therapies (COMBIO) in patients with refractory/overlapping immune-mediated inflammatory diseases (IMIDs) has increased, but reported data remain scarce. We aimed to assess effectiveness and safety of COMBIO in patients with IMIDs.
Methods
We conducted a French ambispective multicenter cohort study from S...
Introduction:
There are currently no comparative data on the efficacy and safety of vedolizumab and ustekinumab in ulcerative colitis (UC) after anti-TNF therapy fails.
Methods:
We retrieved the full datasets of two observational, multicentre, retrospective studies of patients with UC for whom anti-TNF therapy failed and the patients were then t...
Background
Owing to growing number of therapeutic options with similar efficacy and safety, we compared the acceptability of therapeutic maintenance regimens in inflammatory bowel disease (IBD).
Methods
From a nationwide study (24 public or private centers), IBD patients were consecutively included for 6 weeks. A dedicated questionnaire including...
Background and aims
There is no consensus on the management of immune checkpoint inhibitor (ICI) for treating cancer in patients with pre-existing inflammatory bowel disease (IBD). The Groupe d’Étude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID) aimed to provide recommendations on this topic.
Methods
A dedicated working gro...
Background
Despite an effective vaccine, hepatitis B remains a major global health problem due to its significant morbidity and mortality. Vaccination in immunosuppressed patients such as those treated for an inflammatory bowel disease (IBD) can be less effective. This case describes an uncommon original diagnosis of an acute hepatitis B infection...
Background The identification of early prognostic factors during Crohn's disease (CD) remains needed for physician decision-making to minimize structural bowel damage, which this study aimed to assess in a population-based setting.
Methods All incident cases of CD were prospectively registered from 1994 to 1997 in Brittany, a limited area of France...
Our objectives were to better characterize the colorectal function of patients with Spina Bifida (SB). Patients with SB and healthy volunteers (HVs) completed prospectively a standardized questionnaire, clinical evaluation, rectal barostat, colonoscopy with biopsies and faecal collection. The data from 36 adults with SB (age: 38.8 [34.1–47.2]) were...
Background
The exact rate of contraindications to anti-TNF therapy and physician perspectives on treatment choices facing to anti-TNF contraindication, are poorly reported.
Methods
A two-week cross-sectional study was conducted in 31 centres. Physicians completed a questionnaire for a total of 1,314 consecutive outpatients with Crohn's disease, as...
Background:
Iron deficiency (ID) is a frequent condition in patients with inflammatory bowel disease (IBD).
Aim:
Our aim was to investigate the prevalence of ID in patients with IBD.
Methods:
This was a prospective multicenter cross-sectional study conducted in 21 gastroenterology departments in France between January and March 2020. All adult...
Background:
Crohn's disease (CD) is complicated by perianal fistulas in approximately 20% of patients. Achieving permanent fistula closure remains a challenge for physicians. An association between serum anti-tumor necrosis factor-α concentrations and clinical outcomes in patients with CD has been demonstrated; however, little information is avail...
Background: Updating French clinical guidelines for diagnostic and management of ulcerative colitis is needed due to the emergence of new treatments and treatment goals. Methods: On behalf of the Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID), French clinical guidelines were updated through a validated proces...
Background & Aims
Optimal management of patients with inflammatory bowel disease (IBD) after anti-TNF discontinuation due to severe induced skin lesions is unclear. Our study aimed to describe dermatological and IBD evolution after anti-TNF discontinuation for this side effect.
Methods
We conducted a multicenter retrospective study including conse...
Background
Total coloproctectomy with ileoanal anastomosis (IAA) is the procedure of choice for patients with treatment-resistant ulcerative colitis (UC). It is most often curative, but can be complicated by pouchitis in 30% of cases, which becomes chronic in 10% of patients. Its treatment is not codified after failure of conventional treatments an...
Background
Patients with Inflammatory Bowel Disease (IBD), either Crohn’s Disease (CD) or Ulcerative Colitis (UC), treated with immunosuppressants and/or biotherapy might have an altered immune response to SARS-CoV-2 infection. The aim of this study was to evaluate the incidence of COVID-19 in a French cohort of IBD patients treated with infliximab...
Background
Several therapeutic options are now available in ulcerative colitis after anti-TNF failure, but no data compared hitherto tofacitinib and vedolizumab.
We compared the effectiveness of tofacitinib and vedolizumab in UC patients with prior exposure ≥ 1 anti-TNF.
Methods
In this multicentre retrospective study, we consecutively included al...
Background
Data to manage patients with Inflammatory Bowel Disease (IBD) after anti-TNF discontinuation due to severe induced skin lesions are scarce. Our study aimed to assess dermatological and IBD outcomes after discontinuation of an anti-TNF agent related to skin side effects.
Methods
We conducted a multicenter retrospective study including co...
Background and aims
Patients with inflammatory bowel diseases (IBD) are exposed to drug-related nephrotoxicity and kidney-related extra-intestinal manifestations (EIMs). Patients should be monitored but guidance is lacking in current international recommendations. The objective of the Kidney Function Monitoring in Inflammatory Bowel Disease (MONITO...
Introduction
Les associations de traitements ciblés biologiques ou synthétiques (COMBIO) ont vue leur intérêt progresser ces dernières années, chez des patients une maladie inflammatoire à médiation immunitaire (IMID) réfractaire ou chez des patients avec plusieurs IMIDs.
Matériels et méthodes
Nous avons conduit une étude de cohorte entre septembr...
Background
Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In a previous phase 2 induction study, etrolizumab significantly improved clinical remission versus placebo in patients with moderately to severely active ulcerative colitis. We aimed to compare the safety and efficacy of etrolizumab with infliximab in patients with mode...
Background:
The prevalence of obesity and the number of bariatric surgeries in both the general population and in patients with inflammatory bowel disease (IBD) have increased significantly in recent years. Due to small sample sizes and the lack of adequate controls, no definite conclusions can be drawn from the available studies on the safety and...
Background
Phase III trials have demonstrated the efficacy and safety of ustekinumab in ulcerative colitis (UC), but few real-life long-term data are currently available.
Aims
To assess the real-world effectiveness and safety of ustekinumab in patients with UC.
Methods
From January to September 2019, all consecutive patients with active UC treate...
Background
The risk of relapse after anti-tumour necrosis factor [TNF] therapy cessation in Crohn’s disease [CD] patients with perianal fistulas is unclear. We aimed to assess the risk of relapse after anti-TNF cessation in a large cohort and to identify risk factors.
Methods
A systemic literature search was conducted to identify cohort studies re...
Background
Phase III trials have demonstrated the efficacy and safety of ustekinumab in moderate-to-severe ulcerative colitis (UC), but no real-life long-term data is currently available.
Methods
From January to September 2019, all consecutive patients with active UC treated with ustekinumab in a GETAID centre were included. Patients were evaluate...
Background:
The burden of inflammatory bowel disease (IBD) is rising worldwide. The goal of IBD treatment is to achieve clinical and endoscopic remission but also prevent disability.
Aims:
To identify the predictive factors of disability in a large population of patients with IBD.
Patients and methods:
We conducted a cross-sectional survey in...
Background: The treatment of inflammatory bowel diseases is constantly evolving through the emergence of novel molecules and treatment goals. Implementing those progresses in daily clinical practice is necessary. Methods: Thirty-one gastroenterologists practicing in France were invited to participate in a one-day consensus meeting to update previou...
Background
The increased risk of upper gastrointestinal bleeding (UGIB) related to direct oral anticoagulants (DOACs) as compared to vitamin K antagonists (VKA) remains debated.
Aims
To describe the epidemiology and outcomes of UGIB in patients treated with oral anticoagulants.
Methods
A prospective, multicentre study in French general hospitals...
Background:
The prevalence of inflammatory bowel diseases (IBD) is high in women of childbearing age. Achieving clinical remission from conception to delivery using current medications is a major issue in IBD.
Aims:
To assess maternal and neonatal complications and management of vedolizumab or ustekinumab) in pregnant women with IBD receiving th...
Background and aims
The natural history of perianal Crohn’s disease (PCD) remains poorly described and is mainly based on retrospective studies from referral centres. The aim of this study was to assess the incidence, outcomes and predictors of the onset of PCD.
Methods
All incident cases of patients diagnosed with possible CD were prospectively r...
Introduction
The inflammatory bowel disease (IBD)-disk is a 10-item self-questionnaire that is used to assess IBD-related disability. The aim of the present study was to evaluate this tool in the assessment of IBD daily-life burden.
Patients and methods
A one-week cross-sectional study was conducted in 42 centres affiliated in France and Belgium....
Background:
Abdominal or pelvic radiotherapy in inflammatory bowel disease (IBD) patients raises concerns regarding the risk of worsening of underlying disease.
Aim:
To assess the impact of radiotherapy on IBD course.
Methods:
A retrospective multicentre study including IBD patients exposed to abdominal or pelvic irradiation was conducted, ret...
Introduction
While endoscopic balloon dilation (EBD) is widely used to manage ileal strictures, EBD of colorectal strictures remains poorly investigated in Crohn’s disease (CD).
Methods
We performed a retrospective study that included all consecutive CD patients who underwent EBD for native or anastomotic colorectal strictures in 9 tertiary center...
Background
Little is known about the pathophysiological mechanisms of solitary rectal ulcer syndrome (SRUS).
Aims
We aim to identify the different phenotypes, taking into account complaints, anatomy and anorectal physiology.
Methods
Complaints, endoscopy results, and physiology data of patients with histologically proven SRUS were collected and a...
Background
Patients’ experience with healthcare professionals could influence their clinical outcomes.
Aims
To assess inflammatory bowel disease (IBD) patients’ experience with their disease, their treatment and their relationship with their physician.
Methods
A one-week cross-sectional study was conducted in 42 IBD centres. 2011 consecutive outp...
Objectifs
Plusieurs études ont suggéré que les patients spina bifida pourraient avoir une moins bonne réponse aux injections de toxine botulique A (BTX-A) intradétrusoriennes que les autres populations neurologiques sans qu’une hypothèse physiopathologique claire ne permette de l’expliquer. L’objectif de cette étude était d’évaluer l’association en...
Background
New treatments and therapeutic approaches repeatedly emerged in the field of inflammatory bowel disease.
Aim
to update the French treatment algorithms for Crohn's disease (CD) and ulcerative colitis (UC).
Methods
A formal consensus method was used to determine changes to the treatment algorithms for various situations of CD and UC. Thi...
Objectifs
L’objectif de cette étude était d’évaluer l’association entre 6 marqueurs urinaires (NGF, BDNF, TIMP-2, TGF-B1 et PGE2) et l’insuffisance sphinctérienne chez les adultes spina bifida.
Méthodes
Une étude prospective monocentrique a été menée entre mars 2015 et mars 2017 incluant tous les patients spina bifida adultes ayant consulté conséc...
Bowel intussusception is uncommon during adulthood and represents 1% to 5% of all bowel obstruction mainly involving the small bowel. Although most of small bowel intussusception during childhood remains idiopathic, malignant or benign tumors and post-operative complications are usually the underlined diagnosed beyond the intussusception for adults...
Background:
There are few data concerning patients with Crohn's disease (CD) complicated by a stricture of the upper gastrointestinal tract (UGT).
Aims:
We evaluated the outcome and management of CD patients complicated by a stricture of the UGT.
Methods:
We performed a retrospective multicenter study including all CD patients with a non-passa...
For patients at high risk of anal cancer, annual screening strategies using invasive evaluation methods are stressful. According to a normal examination at baseline using simple and non invasive tests, the aim of the work was to quantify neoplastic events.
Patients and method:
Data from patients with a normal evaluation at the first visit were re...
Introduction:
The approved maintenance regimens for ustekinumab in Crohn's disease (CD) are 90 mg every 8 or 12 weeks. Some patients will partially respond to ustekinumab or will experience a secondary loss of response. It remains poorly known if these patients may benefit from shortening the interval between injections.
Methods:
All patients wi...
Objectives
The aim of this study was to investigate the disease-specific urinary levels variations of neurotrophins (NGF, BDNF), mediators of inflammation (TGFβ-1, PGE-2) and markers of extracellular matrix alterations (TIMP-2) in patients with multiple sclerosis (MS) spinal cord injury (SCI), or spina bifida (SB), and neurogenic detrusor overactiv...
Purpose
The medico‐surgical strategy for the treatment of perianal fistulising Crohn’s disease following surgical drainage remains challenging and debated. The aims were to describe the failure rate of therapeutic interventions after drainage of the fistula tract and to determine the factors associated with failure to optimize medico‐surgical strat...
Background:
Magnetic resonance imaging [MRI] is a promising tool to evaluate therapeutic efficacy in ileocolonic Crohn's disease [CD].
Aims:
We aimed to assess the feasibility of early MRI evaluation (week 12 [W12]) to predict corticosteroid-free remission [CFREM] at W52 and prevent long-term bowel damage.
Methods:
All patients with active CD...
There is no consensus on the treatment for solitary rectal ulcer syndrome (SRUS). This study aimed to obtain information from physicians treating patients with SRUS in a French medical surgical society to facilitate management plans and to develop a support algorithm. Members of the French National Society of Coloproctology (SNFCP) were invited to...
Background and aims:
Inflammatory bowel diseases (IBD) are disabling disorders. The IBD-Disability Index (IBD-DI) was developed for quantifying disability in IBD patients but is difficult to use. The IBD-Disk is a visual adaptation of the IBD-DI. It has not been validated yet. The main objectives were to validate the IBD-Disk, to assess the clinic...
Background:
Inflammatory Bowel Diseases (IBD) affect psychological, family, social and professional dimensions of patients' life, leading to disability which is essential to quantify as part of Patient-Reported Outcomes (PROs) newly included in the targets to reach in IBD patients. Up to now, the IBD-Disability Index (IBD-DI) was the only validate...
Citations
... A multicentre, parallel-group, open-labelled RCT with a 52-week follow-up led by Amiot et al showed that combination therapy with infliximab and azathioprine with rapid steroid discontinuation commenced in-hospital was more effective than azathioprine with a standard 8-week tapering regimen to prevent treatment failure. 42 Other monoclonal antibodies used for the treatment of moderate to severe UC in the outpatient setting have not been assessed in a RCT for the treatment of patients hospitalised with UC. The utility of advanced combination therapy (ACT) with an anticytokine approach using a second biologic or novel small-molecule inhibitor is also an avenue worthy of exploration in ASUC given the results of the VEGA trial. ...
... Among those with relapse, however, for retreatment with anti-TNF induced remission in 24 or 29 patients (82.8%) [41], 12 patients (27.3%) required defunctioning surgery and one patient required a proctectomy. The radiological remission of pCD prior to the cessation of anti-TNF had a somewhat more favorable prognosis with only five of the 17 patients (35.3%) relapsing but with a median of 6 months [42]. A more recent meta-analysis of 309 patients from 12 studies by Huinink et al. [42] showed similar outcomes with 75/168 (45%) patients developing a relapse of pCD after the discontinuation of anti-TNF therapy after a median follow up of 11 months [42]. ...
... In the same study, Chojnacki et al. detected mitochondrial fragmentation in DSS-treated mice and colonic tissue from UC patients compared to wild-type mice and healthy controls, suggesting a correlation between mitochondrial fission and inflammation. These results are in line with two other studies associating higher levels of phosphorylated DRP1 and mitochondrial fission with inflammation [44] and mitochondrial fusion with mucosal repair [45]. Another study observed increased gene expression of mitochondrial dynamics proteins (Drp1, Fis1, Opa1, Mfn1 and Mfn2) and higher levels of phosphorylated DRP1 in DSS-treated mice [46], in agreement with previous studies. ...
... 33 Likewise, a recent study from France reported rates of overweight and obesity in 24.1% and 12.2% of patients with IBD. 34 In turn, according to an analysis with a large healthcare database from the USA, bariatric surgery or weight loss medications lowered the risk for developing IBD 35 ; however, a similar study demonstrated the opposite effect. 36 Collectively, these studies indicate that obesity and related comorbidities are on the rise in patients with IBD (as similarly observed in the general population), and that obesity is a risk factor for the development of CD and complications (such as perianal disease). ...
... Though not life-threatening, fatigue severely affects the quality of life (QoL) of infertile women [27]. Despite regional variations in reported incidence [28][29][30][31][32], a recent meta-analysis estimated the global prevalence of general fatigue at 20.4% in adults and 11.7% in minors [33]. Studies from 2011 highlighted that 7-45% of the U.S. population experiences persistent fatigue [34]. ...
... As many CD-related SBAs are associated with bowel wall thickening of over 10 mm, this threshold has been proposed as a cutoff value, above which the presence of malignancy should be suspected [37]. ...
... This raises questions regarding potential de-escalation of treatment for patients in stable remission. The recent SPARE trial investigated clinical relapse in CD patients in steroidfree clinical remission for a minimum 8 months under combined infliximab and immunomodulator therapy who either continued combination therapy or stopped infliximab or immunosuppressive therapy.(80) In this study with 211 randomized CD Downloaded from https://academic.oup.com/ecco-jcc/advance-article/doi/10.1093/ecco-jcc/jjae091/7693895 by guest on 15 ...
... affect the risk of COVID-19, contrary to the presumption that immunosuppressed individuals would be more susceptible to COVID-19 and severe COVID-19 [28]. In a study, Aziz et al. reported that in IBD patients receiving immunosuppressive drugs, SARS-COV-2 reduced ACE2 expression in the gastrointestinal tract of IBD patients [29]. ...
... second biologic), and UST (as second vs. third biologic) was assumed to be the same. Recent comparisons of VDZ and UST in the second or third position showed similar levels of effectiveness.[33][34][35] In contrast, position-specific effectiveness data were available for ADA as first versus second biologic treatment, and VDZ as first biologic administered to biologicnaive patients. ...
... The primary complications experienced by patients with and without IBD were anemia and ferritin and vitamin B 12 deficiencies. Similarly, a French database study reported no statistically significant differences in post-operative complications between patients who underwent bariatric surgery with IBD and without IBD [22]. In contrast to the above-mentioned literature, our results showed significantly higher overall complications in patients who underwent SG and also suffered from IBD. ...